Optimizing the Pharmacokinetics of Sonidegib in Small Bowel Syndrome and Advanced Basal Cell Carcinoma: Our Solution

Main Article Content

Hailey Grubbs
Marianne Cortes
John Strasswimmer


sonidegib, vismodegib, advanced basal cell carcinoma, basal cell carcinoma, Hedgehog pathway inhibitor, skin cancer, dosing strategies, alternate dosing, comorbidities, intestinal malabsorption, dysphagia, treatment, pharmacokinetics, cutaneous oncology, oncology


1. Asgari MM, et al. JAMA Dermatol. 2015;151(9):976–81.

2. Marzuka AG, Book SE. Yale J Biol Med. 2015;88:167–79.

3. Amici JM, et al. Eur J Dermatol. 2015;25(6):586–94.

4. Kim JYS, et al. J Am Acad Dermatol. 2018;78(3):540–59.

5. Cortes JE, et al. Cancer Treat Rev. 2019;76:41–50.

6. Jain S, et al. OncoTargets Ther. 2017;10:1645–53.

7. ODOMZO® (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA. 2019.

Most read articles by the same author(s)